Affordable Access

deepdyve-link
Publisher Website

Autoimmune Cytopenias Developing Late Post Alemtuzumab-Based Allogeneic Stem Cell Transplantation: Presentation of Short Case Series from a Transplant Center.

Authors
  • Lloyd, Rebecca1
  • Nikolousis, Emmanouil1
  • Kishore, Bhuvan1
  • Lovell, Richard1
  • Shankara, Paneesha1
  • Zeid, Nervana Abou1
  • Horgan, Claire1
  • Panteliadou, Alkistis Kyra1
  • McIlroy, Graham1
  • Xenou, Evgenia1
  • Kaparou, Maria1
  • Holder, Kathleen1
  • Murthy, Vidhya1
  • Kanellopoulos, Alexandros1
  • 1 University Hospitals Birmingham NHS, Bone Marrow Transplant Unit Heartlands Hospital, Birmingham, UK.
Type
Published Article
Journal
Cell Transplantation
Publisher
SAGE Publications
Publication Date
Jan 01, 2020
Volume
29
Identifiers
DOI: 10.1177/0963689720950641
PMID: 32806929
Source
Medline
Keywords
Language
English
License
Unknown

Abstract

Stem cell transplantation remains the curative option for many patients with hematological malignancies. The long-term effects of these treatments on the patients and their immune systems have been extensively investigated, but there remains a paucity of data regarding autoimmune manifestations post-transplant, although these effects are well recognized.Herein we present the clinical picture and therapeutic approach in three patients (cases 1-3), with varied presentations of autoimmune disease post-transplant. Case 1 exhibited autoimmune hemolytic anemia and other autoimmune manifestations (serositis, thyroiditis), that were probably linked to graft versus relapsed leukemia effect. Cases 2 and 3 had pure red white cell aplasia and pure red cell aplasia, respectively, which were associated with hyperglobulinemia and a clonal T cell expansion.

Report this publication

Statistics

Seen <100 times